These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 38358447)
1. Additional Information About Pegcetacoplan for Treatment of Geographic Atrophy Growth. Bressler NM JAMA Ophthalmol; 2024 Feb; 142(2):86. PubMed ID: 38358447 [No Abstract] [Full Text] [Related]
2. Treatment of geographic atrophy: an update on data related to pegcetacoplan. Patel SB; Heier JS; Chaudhary V; Wykoff CC Curr Opin Ophthalmol; 2024 Jan; 35(1):64-72. PubMed ID: 37815317 [TBL] [Abstract][Full Text] [Related]
3. Pegcetacoplan treatment for geographic atrophy due to age-related macular degeneration: a plain language summary of the FILLY study. Liao DS; Metlapally R; Joshi P Immunotherapy; 2022 Sep; 14(13):995-1006. PubMed ID: 35860926 [TBL] [Abstract][Full Text] [Related]
4. Pegcetacoplan (Syfovre) for geographic atrophy in age-related macular degeneration. Med Lett Drugs Ther; 2023 Apr; 65(1673):49-50. PubMed ID: 37020339 [No Abstract] [Full Text] [Related]
6. Association of Pegcetacoplan With Progression of Incomplete Retinal Pigment Epithelium and Outer Retinal Atrophy in Age-Related Macular Degeneration: A Post Hoc Analysis of the FILLY Randomized Clinical Trial. Nittala MG; Metlapally R; Ip M; Chakravarthy U; Holz FG; Staurenghi G; Waheed N; Velaga SB; Lindenberg S; Karamat A; Koester J; Ribeiro R; Sadda S JAMA Ophthalmol; 2022 Mar; 140(3):243-249. PubMed ID: 35113137 [TBL] [Abstract][Full Text] [Related]
7. Impact of Baseline Characteristics on Geographic Atrophy Progression in the FILLY Trial Evaluating the Complement C3 Inhibitor Pegcetacoplan. Steinle NC; Pearce I; Monés J; Metlapally R; Saroj N; Hamdani M; Ribeiro R; Rosenfeld PJ; Lad EM Am J Ophthalmol; 2021 Jul; 227():116-124. PubMed ID: 33675755 [TBL] [Abstract][Full Text] [Related]
9. Re: Patel et al.: A cost-effectiveness analysis of pegcetacoplan for the treatment of geographic atrophy. (Ophthalmol Retina. 2024;8:25-31). Shen LL; Del Priore LV Ophthalmol Retina; 2024 Feb; 8(2):e3. PubMed ID: 37865911 [No Abstract] [Full Text] [Related]
10. Pegcetacoplan: First Approval. Hoy SM Drugs; 2021 Aug; 81(12):1423-1430. PubMed ID: 34342834 [TBL] [Abstract][Full Text] [Related]
11. A Cost-Effectiveness Analysis of Pegcetacoplan for the Treatment of Geographic Atrophy. Patel NA; Al-Khersan H; Yannuzzi NA; Lin J; Smiddy WE Ophthalmol Retina; 2024 Jan; 8(1):25-31. PubMed ID: 37572871 [TBL] [Abstract][Full Text] [Related]
12. Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Phase 2 Trial. Liao DS; Grossi FV; El Mehdi D; Gerber MR; Brown DM; Heier JS; Wykoff CC; Singerman LJ; Abraham P; Grassmann F; Nuernberg P; Weber BHF; Deschatelets P; Kim RY; Chung CY; Ribeiro RM; Hamdani M; Rosenfeld PJ; Boyer DS; Slakter JS; Francois CG Ophthalmology; 2020 Feb; 127(2):186-195. PubMed ID: 31474439 [TBL] [Abstract][Full Text] [Related]
13. Predicting Topographic Disease Progression and Treatment Response of Pegcetacoplan in Geographic Atrophy Quantified by Deep Learning. Vogl WD; Riedl S; Mai J; Reiter GS; Lachinov D; Bogunović H; Schmidt-Erfurth U Ophthalmol Retina; 2023 Jan; 7(1):4-13. PubMed ID: 35948209 [TBL] [Abstract][Full Text] [Related]